Karyopharm Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $34,079 | $44,044 | $37,929 | $30,015 |
Gross Profit | 32,595 | 41,931 | 36,878 | 28,714 |
EBITDA | -17,825 | -22,560 | -25,906 | -12,354 |
EBIT | -17,844 | -22,638 | -25,984 | -12,432 |
Net Income | -102,198 | -33,127 | -37,252 | -23,462 |
Net Change In Cash | 34,079 | 44,044 | 37,929 | 30,015 |
Free Cash Flow | -11,828 | -5,860 | -18,697 | -38,984 |
Cash | 60,540 | 37,672 | 38,725 | 38,783 |
Basic Shares | 17,979 | 8,669 | 8,620 | 8,470 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $146,067 | $145,237 | $146,033 | $157,074 |
Gross Profit | 140,118 | 139,230 | 141,091 | 151,861 |
EBITDA | -90,411 | -38,603 | -118,423 | -139,305 |
EBIT | -90,707 | -38,943 | -118,953 | -139,926 |
Net Income | -196,039 | -76,422 | -143,099 | -165,291 |
Net Change In Cash | 146,067 | 145,237 | 146,033 | 157,074 |
Cost of Revenue | -60,072 | |||
Free Cash Flow | -75,369 | -127,628 | -92,723 | -149,672 |
Cash | 60,540 | 62,476 | 52,231 | 135,188 |
Basic Shares | 10,935 | 8,124 | 7,614 | 5,458 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | -$5.69 |
2025-09-30 | -$3.82 |
2025-06-30 | -$4.07 |
2025-03-31 | -$2.77 |
